Influence of periodontal conditions on quality of life in patients with chronic kidney disease: A systematic review and meta-analysis.

Med Oral Patol Oral Cir BucalSep 1, 2026 (epub)
Clinical ResearchNephrology

C Schöffer, C-C Del'Agnese, E-L Marder et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of periodontal conditions on oral health-related quality of life (OHRQoL) in patients with chronic kidney disease (CKD). Seven studies involving patients with end-stage renal disease (ESRD) were analyzed. Results indicated that those with stage III/IV periodontitis had significantly higher OHIP-14 scores (MD: 1.88; 95%CI: 0.67-3.09; p=0.002) compared to those without periodontitis or with milder forms.

Key findings

  • Patients with ESRD had higher OHIP-14 scores compared to healthy controls.
  • Stage III/IV periodontitis was associated with an MD of 1.88 in OHIP-14 scores.
  • A weak positive correlation was found between periodontal probing depth and OHIP-14 scores (r=0.145; p=0.028).
  • Plaque index showed a significant correlation with OHIP-14 scores (r=0.385; p<0.001).

Why it matters

Understanding the relationship between periodontal health and OHRQoL in CKD patients is crucial for improving patient care. Addressing periodontal issues may enhance the overall quality of life for these individuals.

Source

PubMed · PMID 42001496

Published in Med Oral Patol Oral Cir Bucal. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.